Portal de investigação
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Autores da FMUP
Participantes de fora da FMUP
- Parigi, TL
- D'Amico, F
- Abreu, M
- Dignass, A
- Dotan, I
- Griffiths, AM
- Jairath, V
- Iacucci, M
- Mantzaris, GJ
- O'Morain, C
- Reinisch, W
- Sachar, DB
- Turner, D
- Yamamoto, T
- Rubin, D
- Peyrin-Biroulet, L
- Ghosh, S
- Danese, S
Unidades de investigação
Abstract
Many patients with inflammatory bowel disease (IBD) have persistent symptoms and disease activity despite the best available medical or surgical treatments. These patients are commonly referred to as having difficult-to-treat IBD and need additional therapeutic strategies. However, the absence of standard definitions has impeded clinical research efforts and comparisons of data. Under the guidance of the endpoints cluster of the International Organization for the Study of Inflammatory Bowel Disease, we held a consensus meeting to propose a common operative definition for difficult-to-treat IBD. 16 participants from 12 countries voted on 20 statements covering various elements of difficult-to-treat IBD, such as failure of medical and surgical treatments, disease phenotypes, and specific complaints from patients. "Agreement" was defined as at least 75% consensus. The group agreed that difficult-to-treat IBD is defined by the failure of biologics and advanced small molecules with at least two different mechanisms of action, or postoperative recurrence of Crohn's disease after two surgical resections in adults, or one in children. In addition, chronic antibiotic-refractory pouchitis, complex perianal disease, and comorbid psychosocial complications that impair disease management also qualified as difficult-to-treat IBD. Adoption of these criteria could serve to standardise reporting, guide enrolment in clinical trials, and help identify candidates for enhanced treatment strategies.
Dados da publicação
- ISSN/ISSNe:
- 2468-1253, 2468-1253
- Tipo:
- Review
- Páginas:
- 853-859
- Link para outro recurso:
- www.scopus.com
LANCET GASTROENTEROLOGY & HEPATOLOGY Elsevier Ltd.
Citações Recebidas na Web of Science: 8
Citações Recebidas na Scopus: 28
Documentos
- Não há documentos
Filiações
Keywords
- CROHNS-DISEASE; ULCERATIVE-COLITIS; ANTI-TNF; METAANALYSIS; PREVALENCE; PREDICTORS; REMISSION; EFFICACY
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Parigi TL,D'Amico F,Abreu M,Dignass A,Dotan I,Magro F,Griffiths AM,Jairath V,Iacucci M,Mantzaris GJ,O'Morain C,Reinisch W,Sachar DB,Turner D,Yamamoto T,Rubin D,Peyrin L,Ghosh S,Danese S. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol. Hepatol. 2023. 8(9):p. 853-859. IF:35,700. (1).
